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Abstract
Background: Although hemophilia has a potentially high economic impact, there are no published estimates of
healthcare costs for this disease in Portugal. The aim of this study was to evaluate costs of treatment and hospital
utilization among patients with hemophilia A and B, with and without inhibitors, over a 3-year period in a
Portuguese Comprehensive Care Hemophilia Centre. This is the first study on the financial impact of healthcare
costs in patients with hemophilia in Portugal.
Methods: This retrospective, observational study identified patients diagnosed with hemophilia A and B using
medical and pharmacy electronic medical records and data from Centro Hospitalar São João, between January 2011
and December 2013. Patients with inhibitors were all high responders (>5 Bethesda Units [BU]). Severity was
classified as mild, moderate or severe based on clotting factor levels. Two main outcomes were measured: (1) cost
associated with hospital pharmacy claims (clotting factor) and (2) number of hospital visits/hospitalization.
Results: A cohort of 103 patients were identified: 72 (69.9 %) with hemophilia A and 31 (30.1 %) with hemophilia B.
Among these, five individuals were classified as patients with inhibitors (four with hemophilia A and one with
hemophilia B). From the cohort of hemophilia A patients, 36 individuals (35.0 %) were identified as having severe
disease; 20 (19.4 %) moderate; and 16 (15.5 %) mild. In the cohort of hemophilia B patients, 14 (13.6 %) were
identified as having severe disease; 14 (13.6 %) moderate; and three (2.9 %) mild. The total mean aggregate cost
per year (including clotting factor and hospital utilization) for patients with severe hemophilia B was €112,469,
compared with €793 for mild hemophilia A. Clotting factor concentrate amounted for 90 % of total cost in severe
cases and hospital utilization was also higher in these cases.
Conclusions: Hemophilia treatment is expensive, particularly for patients with severe disease and especially if they
develop inhibitors to replacement clotting factors. In our study, severe hemophilia is associated with greater annual
total costs in both types of hemophilia (A = €77,587 and B = € 112,469). Patients with inhibitors have costs 3.3 times
higher than patients without inhibitors. Age was not associated with significantly greater total costs (clotting factor
and hospital visits/hospitalizations).
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Abstract (Portuguese)
Introdução: Apesar da hemofilia possuir um impacto económico importante, não existem estimativas publicadas
sobre os custos desta patologia em Portugal. O objectivo deste trabalho foi a avaliação da despesa em cuidados de
saúde dos doentes com hemofilia A e B, no contexto de um Centro Compreensivo de Hemofilia Português. Este é
o primeiro estudo do impacto financeiro dos custos do tratamento de doentes com hemofilia em Portugal.
Métodos: Foram utilizados neste estudo retrospectivo e observacional os registos médicos electrónicos do Centro
Compreensivo de Hemofilia do Centro Hospitalar São João, no período de Janeiro 2011 a Dezembro 2013. Foram
identificados os doentes com hemofilia A e B assim como os doentes com inibidores. Os doentes com inibidores
eram todos altos respondedores (>5 Unidades Bethesda). A hemofilia foi classificada como grave, leve ou
moderada, consoante o nível de factor. Foram usados dois pontos (variáveis?): o custo associado ao concentrado
de factor e o número de consultas/internamentos.
Resultados: Foram identificados 103 doentes: 72 (69.9 %) com hemofilia A e 31 (30.1 %) com hemofilia B. Cinco
doentes tinham inibidores (4 com hemofilia A e 1 com hemofilia B). No grupo de doentes com hemofilia A, 36
(35.0 %) são graves, 20 (19.4 %) moderados e 16 (15.5 %) leves. No caso da hemofilia B, 14 (13.65 %) são graves,
14 (13.6 %) moderados e 3 (2.9 %) leves. A média anual de custos (incluindo os concentrados de factor da
coagulação e os episódios registados no hospital) variou entre €112,469 para a hemofilia B grave, e €793 para a
hemofilia A leve. Nos doentes com hemofilia grave, os concentrados de factores da coagulação foram
responsáveis por 90 % dos custos e as consultas externas, episódios de urgência e internamentos foram também
mais elevados.
Conclusões: O tratamento da hemofilia possui custos elevados, nomeadamente nos doentes com hemofilia
grave e/ou com inibidores. No nosso estudo, os doentes hemofílicos com maior gravidade estão associados com
custos totais anuais mais elevados nos dois tipos de hemofilia (A = €77,587 e B = € 112,469) e os doentes com
inibidores têm custos 3.3 vezes mais elevados do que os doentes sem inibidores. Além disso, não se identificou
uma associação estatisticamente significativa entre a idade e os custos totais (concentrado de factor e utilização
hospitalar).
Background
Hemophilia is a rare genetic disease linked to the X-
chromosome. The presence of specific genetic mutations
results in an inability to produce the clotting factors needed
to stop bleeding. The two most common types are
hemophilia A, a deficiency of clotting Factor VIII; and
hemophilia B, a deficiency of clotting Factor IX. Hemophilia
A affects one in 5000–10,000 and hemophilia B one in
25,000–30,000 male births [1]. Although hemophilia is
largely an inherited bleeding disorder, approximately one-
third of patients present with no prior family history; in
these patients, hemophilia results from a de novo gene
mutation [2].
The treatment of hemophilia is based on clotting factor
replacement therapy. The most commonly used treatments
for hemophilia are “on-demand” therapy and factor
prophylaxis. During a bleeding episode, clotting factor can
be given “on-demand” to control and stop the bleeding;
however, this type of therapy does not prevent the develop-
ment of hemarthrosis (a bleeding into joint spaces) or its
consequences. During prophylactic treatment, patients
receive regular factor concentrate replacement therapy,
which can lead to better clinical outcomes, with a lower
overall impact on quality of life; however, this type of treat-
ment is more expensive than “on-demand” therapy [3, 4].
Over the past 30 years, the life expectancy of people
with hemophilia has significantly increased, largely due
to advances in medical care; the introduction and acces-
sibility of safe and effective factor replacement therapies;
and improvements in treatment of infectious diseases.
For example, in Sweden between 1969 and 1980, life
expectancy for a patient with hemophilia receiving factor
replacement therapy was only 58 years [5]. Today, with
the new model of treatment care, life expectancy is simi-
lar to that of people without hemophilia, which creates
new, complex clinical issues not all directly related to
hemophilia [6].
These advances have been achieved at high financial
costs, and hemophilia remains one of the most expen-
sive and challenging diseases to manage. Clotting factor
costs amount to 50–90 % of the total healthcare costs
for hemophilia treatment, depending on severity and
type [7, 8]. In the United States, Globe et al. [9] esti-
mated that the annual medical cost for a patient’s
hemophilia care was $132,102, with clotting factor use
accounting for an average of 72 % of total costs. Excel-
lent clinical results have been demonstrated with high-
dose prophylaxis factor therapy; however, because of the
high costs associated with this treatment, its use should
be assessed based on a cost-benefit evaluation [10].
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Furthermore, some patients with hemophilia develop
inhibitors to replacement clotting factors, which renders
treatment ineffective and results in the requirement for
a different treatment strategy [11]. It is estimated that
inhibitors develop in 25–30 % of severe hemophilia A
patients and 3–5 % of severe hemophilia B patients [12].
In the United States, Guh et al. [13] found that the total
annual cost of treatment for a hemophilia A patient
developing inhibitors was 4.8 times higher than for a pa-
tient without inhibitors [14, 15]. In these cases, immune
tolerance induction is an option; it involves the use of
very high doses of clotting factor, with the aim of desen-
sitizing the patient to the novel protein. This treatment
strategy can eradicate persistent inhibitors in some pa-
tients with severe hemophilia A [16, 17]. However, the
requirement for bypassing agents and immune tolerance
induction in hemophilia patients who develop inhibitors
further increases overall treatment costs [18].
No previous studies on hemophilia costs have been
conducted in Portugal. The Portuguese Association of
Hemophilia (APH) [19] has reported between 700 and
800 registered members; however, this may be an under-
estimation and the overall prevalence of hemophilia in
Portugal is unknown, as there is no national registry. Ac-
cording to the final report of the national working group
established by the government “Despacho N° 4319/2013,
de 15 de Março de 2013”[20], approximately 2400
people in Portugal are thought to have inherited coagu-
lopathies. The difference between these figures may be
due to the fact that people with mild or moderate
hemophilia rarely experience spontaneous bleeding and
may therefore not be identified unless they have an acute
event, such as surgery or an accident. Alternatively,
some individuals do not want to be registered with a pa-
tient association.
Recently, the Direcção-Geral de Saúde (DGS) [21],
under the National Program for Rare Diseases, com-
menced data collection for a nationwide registry for
these rare diseases via the distribution of the “Rare Dis-
ease Patient Card”; therefore, it is expected that in the
near future, an effective and accurate national database
will be accessible.
Data from the Portuguese National Authority to Drugs
and Devices (INFARMED) [22] show an increase of
167.5 % in hospital costs for hemostatic drugs between
2008 and 2013, which represents approximately 4 % of
total national costs of hospital drugs (Table 1). Based on
the knowledge that there are approximately 800 people
in Portugal with hemophilia, it can be calculated that an
average of €44,134 is spent by each patient on clotting
factors per year. According to the Organization to Eco-
nomic Co-operation and Development (OECD)[23], ex-
penses on health per capita (private and public) was
€1924 in Portugal, representing about 10.2 % of Gross
Domestic Product (GDP).
The purpose of this study was to evaluate the charac-
teristics and health system costs in patients with
hemophilia by type, age and severity, with and without
inhibitors, over a three-year period, at the Hemophilia
Comprehensive Care Center (CCC) of the University
Hospital, Centro Hospitalar São João - Entidade Pública
Empresarial (CHSJ –EPE).
Methods
A retrospective, observational study was performed,
using medical and pharmacy electronic medical records
and data from CHSJ-EPE, between January 2011 and
December 2013. Patients for this study were selected
from our Hemophilia CCC database if they had at least
one episode registered in our hospital in that period;
Patients were identified according to their hemophilia
type, severity, presence/absence of inhibitors, and age.
Patients with inhibitors were all high responders (>5
BU). Hemophilia severity was classified as mild (5–40 %
of normal factor level), moderate (1–5 % of normal fac-
tor level), or severe (<1 % of normal factor level) [24].
There were six groups established according to type and
severity of hemophilia: (i) patients with severe hemophilia
A; (ii) patients with moderate hemophilia A; (iii) pa-
tients with mild hemophilia A; (iv) patients with severe
hemophilia B; (v) patients with moderate hemophilia B;
(vi) patients with mild hemophilia B. Patients were also
divided by type (A or B) and age: Pediatrics (<18 years)
and adults. Additionally, patients who were human im-
munodeficiency virus (HIV) and/or hepatitis C virus
(HCV)-positive were identified.
Two main outcomes were measured from January
2011 through December 2013: (1) cost associated with
all hospital pharmacy claims (clotting factor) and (2)
number of hospital visits/hospitalization.
Using the CHSJ-EPE Business Intelligence system, pa-
tient data related to drug costs and hospitalization/
Table 1 Total hospital drug costs in Portugal
2008 2009 2010 2011 2012 2013
Total drug costs 573,228 670,028 993,787 1,012,518 1,017,942 974,824
Hemostatic drugs 13,200 21,622 36,793 37,370 36,861 35,307
% of total national costs 2.3 % 3.2 % 3.7 % 3.7 % 3.6 % 3.6 %
Source: INFARMED Unit: M€
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hospital visits were collected. Because in Portugal hos-
pital visits, inpatient admissions and emergencies are
each associated with a specific national funding price,
the costs resulting from hospital visits were calculated
based on hospital reimbursement. Transportation and
diagnosis costs were considered minimal and were
therefore not included in the analysis.
Costs were annualized by computing the sum of total
costs for each patient and dividing by 3. Total costs were
defined as the sum of the two aforementioned costs.
Statistical analysis was performed using SPSS-22
(Statistical Package for the Social Sciences). Differences
in means were tested using the Mann-Whitney U test.
The Kruskal-Wallis test was used to compare more
than two groups. These non-parametric tests were used
because data were not normally distributed.
Results
A total of 103 patients were identified; 72 (69.9 %) had
hemophilia A and 31 (30.1 %) had hemophilia B
(Table 2). Overall, five (4.9 %) expressed inhibitors
(four patients with hemophilia A and one patient with
hemophilia B). In the hemophilia A cohort, 36 pa-
tients (35.0 %) had severe disease; 20 (19.4 %) moderate
disease; and 16 (15.5 %) mild disease. In the hemophilia B
cohort, 14 patients (13.6 %) had severe disease; 14 (13.6 %)
moderate disease; and three (2.9 %) mild disease. A small
number of patients (n = 8; 7.8 %) were HIV-positive and 22
patients HCV-positive (21.4 %). All patients who were
cases HIV-positive or HCV-positive were adults (>38 years
for HIV and >26 years for HCV).
On average, each patient had 13 consultations and six
days of hospital admissions per year. During the study
period, a 19.8 % reduction in consultations and 39.8 % in
day hospital admissions was seen. This was partly due to
the adoption of a prophylactic approach including all chil-
dren with severe hemophilia, as well as improvements in
home therapy following participation in a patient and fam-
ily training program for self-administration of clotting
factors, which has advantages for both patients and the
healthcare system. Of the 21 surgical admissions recorded,
most were in adult patients (n = 19). Surgeries related to
“diseases and disorders of musculoskeletal system and
connective tissue” (namely, orthopedic surgery of the hip
or knee, performed in adults) were 33.3 %, followed by
“diseases and disorders of the nervous system” (23.8 %),
and “diseases and disorders of ear, nose, mouth and
throat” (19.0 %), which were more frequent in children
and teenagers than adults.
The overall healthcare annual costs are shown in
Table 3. Costs for patients in the severe group were con-
siderably higher than costs for those in the mild/moder-
ate groups. For patients identified with hemophilia A,
the annual mean healthcare cost was €77,587 for severe
patients, €8495 for moderate and €793 for those with
mild hemophilia (P = 0.000). Individuals with severe
hemophilia B had the highest total healthcare costs
(mean = €112,469). The unexpectedly high value ob-
tained for patients with mild hemophilia B (€10,217
compared with €793 for patients with mild hemophilia
A) is likely related to the very small number of patients
in this group (n = 3). Only one of these patients had
previously suffered from hemorrhagic transformation of
cerebral septic emboli and, as a result of infectious endo-
carditis, had undergone surgery to insert a prosthesis
mechanical valve in the heart. This procedure, and the
hospitalization-associated costs, significantly increased the
overall clotting factor costs. In both severe hemophilia A
and severe hemophilia B patients, clotting factor accounted
for more than 90 % of the total treatment cost (92 and 93
%, respectively).
As expected, statistically significant differences were
found between patients with and without inhibitors in
total annual costs (Table 4). Costs were higher for
patients with inhibitors (€134,032) than for patients
without inhibitors (€40,138, P = 0.03). Although, the only
patient with severe hemophilia B and inhibitors was a
child, the average annual clotting factor cost for this
patient was seven times higher than for patients with
hemophilia B without inhibitors. This patient had an
anaphylactic reaction to Factor IX concentrate treatment
and an intracranial hemorrhage, which raised the costs
in this group. Accordingly, due to the risk of immune
tolerance and the previously documented low success
rate of Factor IX, it was decided to maintain prophylaxis
Table 2 Demographic characteristics
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with recombinant Factor VIIa. During this period stud-
ied, there was only one patient (a child with severe
hemophilia A) documented to have immune tolerance
therapy, which was associated with a total annual cost of
€317,415.
A key finding in this analysis is that no statistically
significant differences were found between pediatric and
adult patients in both types of hemophilia, despite ther-
apy being related to the patient’s weight (Table 5). For
pediatric patients with hemophilia A, annual costs were
€37,805 while for adults were €49,338 (P = 0.471). For
patients with hemophilia B, these costs were €104,618
and €43,173 (P = 0.815), respectively.
Discussion
The results of our study confirm those of previous stud-
ies on hemophilia costs previously conducted in Europe;
in Italy, Kodra et al. [25] estimated mean direct health-
care costs per patient with hemophilia to be €109,768;
and in Belgium, Henrad et al. evaluated this cost to be
€97,336 [26].
Our findings reveal that a small proportion of patients
with hemophilia (n = 5; 4.9 %) developed inhibitors to
clotting factor products and required treatment with
bypassing agents. However, given the associated costs for
these additional treatments, these patients significantly
contribute to overall global expenditure. In our study,
patients with inhibitors accounted for 3.3 times the annual
cost of patients without inhibitors. It should be noted that
there are now more children with hemophilia who are
reaching adulthood, at which stage they begin individual-
ized prophylaxis treatment. As the cohort of young
patients on prophylaxis treatment grows older and larger,
the demand for factor concentrates will likely increase,
which could lead to increased factor costs as a result.
The total annual costs were not statistically different
between adults and children in both types of hemophilia.
There could be three possible explanations for the simi-
lar costs: as the vast majority of children in this study
were teenagers (median age of ten years), their body
weight would be comparable with adults; the different
pharmacokinetics of clotting factors in children, which
implies a higher consumption clotting factor per kg; and
the model used, as prophylaxis is used in 100 % of chil-
dren and teenagers versus 40–70 % in adults with severe
hemophilia.
Because the number of patients with HIV or HCV in-
fection was small, we did not carry out an analysis compar-
ing infected versus non-infected patients with hemophilia.
Guh et al. [27] previously demonstrated that mean cost of
hemophilia treatment is independent of blood-borne viral
infection status. However, Tencer et al. [28] concluded that
annual medical costs (clotting factor, prescription drugs,
inpatient services and outpatient services) were 59 %
greater in patients with hemophilia who also had HIV and/
or HCV compared with those with hemophilia alone.
There are three important limitations to our study.
The first limitation is that hemophilia is a rare disease;
consequently, it is difficult to collect data on a large co-
hort. Because of this restriction, Farrugia et al. [29] under-
lined the role of observational analysis as a method to
increase the evidence base of hemophilia treatment. The
second limitation is that this study was conducted on a
small scale, with data only being collected from one hos-
pital (including the outpatient or pharmacy departments).
Table 3 Annualized costs, per year, by type and severity (€; Euros)
Hospital utilization Clotting factor Total costs % Clotting factor P-value
Type A
Severe 6486 71,101 77,587 92 % 0.000
Moderate 2469 6026 8495 71 %
Mild 0506 0287 0793 36 %
Type B
Severe 7846 104,623 112,469 93 % 0.000
Moderate 0775 2108 2883 73 %
Mild 1913 8304 10,217 81 %
P values were computed using the KrusKal Wallis test
Table 4 Annualized total costs by inhibitor status (€; Euros)
Total cost P-value
With inhibitor (n = 5) 134,032 0.030
Without inhibitor (n = 98) 40,318
P value was computed using the Mann-Whitney U test
Table 5 Annualized total costs, by type and age (€; Euros)
Total cost P-value
Type A
Adult (n = 50) 49,338 0.471
Pediatric (n = 22) 37,805
Type B
Adult (n = 26) 43,173 0.815
Pediatric (n = 5) 104,618
P value was computed using the Mann-Whitney U test
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In addition, it did not take into consideration other re-
sources used in homecare to manage aspects of the condi-
tion such as breakthrough bleeding, which does not
require a clinic visit (excluding clotting factors, which
were integrated to the calculations). The final limitation is
that the hospital prices used to calculate the total costs are
not the real costs, but hospital reimbursement prices.
However, in the absence of a reliable cost calculation, this
was considered to be an appropriate alternative for an ap-
proach in which factor concentrates represent more than
90 % of overall expenses (in severe patients and patients
with inhibitors).
In the United States, where health expenses per capita
represent 17.7 % of GDP, hemophilia care is delivered in
highly specialized centers, designated as Hemophilia
CCCs, which treat approximately 70 % of people with
this disorder [30]. Hemophilia CCCs offer comprehen-
sive, multidisciplinary hemophilia services, treat a large
number of patients, and have long-standing experience
in the management of this disease, which is needed to
prevent and manage complications, especially in severe
patients [31]. Furthermore, the increasing prevalence of
age-associated diseases, such as cardiovascular patholo-
gies or osteopenia, will pose additional challenges in the
treatment of these patients [32].
This is the first study on the financial impact of
healthcare costs in patients with hemophilia in Portugal.
Despite the rarity of this disease, the high costs associ-
ated with its treatment justify the concentration of
resources and assurance of the most cost-effective care
[33, 34], and therefore have been integrated into a na-
tional strategy for a “more coherent hospital network”.
The Public Health Ministry of Portugal has recently
approved the guidelines for hemophilia treatment [35],
which describe the clinical protocols and the range of
quality indicators that should be evaluated periodically.
CHSJ-EPE was recognized by the European Hemophilia
Network (EUHANET) [36] as a European Hemophilia
CCC, according to the performance and differentiation
of services. This network has 84 centers in 26 countries.
The future development of this project will require the
expansion of measures based on economic, clinical and
quality outcomes [37].
Conclusions
Severe hemophilia is associated with greater annual total
costs in both types of hemophilia (A = €77,587 and B = €
112,469). Patients with inhibitors accounted for 3.3 times
the annual cost of patients without inhibitors. In addition,
age is not associated with significantly bigger total costs
(clotting factor and hospital visits/hospitalizations).
The high costs of hemophilia treatment, coupled with
the requirement for highly specialized therapies, present
a unique challenge for care management and reimburse-
ment considerations for health planning.
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